• Publications
  • Influence
Anthracycline cardiotoxicity: from bench to bedside.
TLDR
The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs and is incorporated into the framework of a broader review of preclinical and clinical issues.
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A
TLDR
The number of childhood cancer survivors is expected to increase as a result of the rising pediatric cancer incidence and improved long-term survival rates and the Childhood Cancer Survivor Study has improved the understanding of the long- term mortality and morbidity in this high-risk population.
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
TLDR
The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised.
Serum Troponins as Biomarkers of Drug-Induced Cardiac Toxicity
TLDR
The objective of this study was to establish a baseline experimental procedure and show direct AFM measurements that unequivocally can be assigned as safe levels of abuse in animals and show real-world implications for human health and animal welfare.
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
The bisdioxopiperazine dexrazoxane (ICRF-187) has proven to be clinically very effective in reducing the cardiotoxicity of doxorubicin and other anthracyclines. Doxorubicin is thought to exert its
Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection
TLDR
Analysis of serum from rat models of anthracycline and anthracenedione induced cardiotoxicity indicate the potential clinical utility of diagnostic proteomic patterns where low molecular weight peptides and protein fragments may have higher accuracy than traditional biomarkers of cardiot toxicity such as troponins.
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
TLDR
Measurements of serum levels of cardiac troponin-T (cTnT) seem to provide a sensitive means for assessing the early cardiotoxicity of doxorubicin.
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats
TLDR
Compared to dexrazoxane, amifostine provided a comparable degree of protection against the nephrotoxicity of doxorubicin, but was less cardioprotective and did not prevent the mortality and loss of body weight produced by doxorbicin.
Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
TLDR
The data support the concept that the chronic cardiomyopathy induced by doxorubicin is not mediated by apoptosis of the cardiac myocytes, as well as showing that significant toxicity in the heart, kidneys and intestine in association with apoptosis in epithelial cells of the intestinal mucosa and renal tubules is induced.
The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity
TLDR
The present study showed that DRZ significantly attenuates the cardiotoxicity induced by DXR and MTX, and that this protective activity can be assessed by morphological evaluation of cardiac tissues and by monitoring the concentrations of cTnT in serum.
...
...